Focused fundamental and scientific investment process

A deep focus on scientific and financial research is essential to our understanding of how regulatory and innovation dynamics influence and affect the marketplace. We invest mostly in publicly-listed therapeutic companies, ranging from early-stage small capitalization biotechnology companies to multinational large capitalization pharmaceutical conglomerates. Our investment specialists aim to capitalize on significant scientific, technological and policy changes. Collectively, we utilize a fundamental research approach anchored in science and financial analysis to identify high-conviction investment opportunities.

We focus on

  • Global Pharmaceuticals
  • Specialty Pharmaceuticals
  • Generics
  • Biotechnology

Risk Management

At NEXTHERA, we offer investors active management and exposure to specialized healthcare sectors. Our intention is to both preserve and grow our investors’ capital within a stringent risk framework, and deliver consistent returns through all stages of the market cycle. NEXTHERA employs this active management strategy alongside risk controls to manage exposure and position limits. We maintain a diversified portfolio and adjust allocations based on the risk embedded in our portfolio companies. The relative risk of targeted investments is considered when sizing allocations within the overall portfolio. In doing so, we attempt to balance risk through position size.

Flexible Net Exposure

We use a “flexible net exposure” that allows us to dynamically capture our view of the macro cycle within healthcare and in its fundamental sub-sectors amid their various shifts and rotations. By tactically expressing our macro view in this manner, we can serve as a true healthcare specialist for our investors.